<DOC>
	<DOC>NCT01289756</DOC>
	<brief_summary>Aim of the study is the clinical validation of the metabolism and the pharmakokinetic of Clomifen in correlation to CYP2D6 and inhibition of CYP3A4.</brief_summary>
	<brief_title>Influence of Pharmacogenetic Factors, Paroxetine and Clarithromycin on Pharmacokinetics of Clomiphene</brief_title>
	<detailed_description />
	<mesh_term>Anovulation</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Healthy Female caucasians Age 18 45 years old BMI 18.5 26 kg/m2 Persons with known sensitivity of Clomifen and/or Paroxetine and/or Clarithromycin Pregnancy/lactation period Meno/postmenopausal Smokers</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>pharmacokinetic</keyword>
	<keyword>clomiphene</keyword>
	<keyword>CYP2D6 polymorphisms</keyword>
	<keyword>inhibition of CYP2D6 and CYP3A4</keyword>
</DOC>